Paid Clinical Trials for Lymphoma

Showing 1 – 20 of 68 results

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL

by CTG

in Lymphoma, Leukemia, Myeloma

Other

Texas

Deadline:

07/01/2035

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

by CTG

in Lymphoma, Leukemia, Hematopoietic and Lymphoid Cell Neoplasm, Central Nervous System Lymphoma, Plasma Cell Myeloma

Other

Texas

Deadline:

10/31/2026

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

by CTG

in Lymphoma, Leukemia

Other

Texas

Deadline:

06/30/2026

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

by CTG

in Lymphoma, Lymphoma, B-Cell

Other

California

Deadline:

04/14/2028

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

by CTG

in Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Non-Hodgkin

Other

North Carolina

Deadline:

11/04/2039

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

by CTG

in Lymphoma, Advanced Solid Tumor

Other

Pennsylvania

Deadline:

12/30/2026

Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

by CTG

in Lymphoma, Leukemia

Other

Texas

Deadline:

12/31/2026

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

by CTG

in Breast Cancer, Lymphoma

Other

Oklahoma

Deadline:

09/01/2027

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

by CTG

in Lymphoma, Marginal Zone Lymphoma, MZL

Other

Massachusetts

Deadline:

02/01/2030

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

by CTG

in Lymphoma

Other

California

Deadline:

12/10/2028

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

by CTG

in Lymphoma

Other

Texas

Deadline:

12/31/2028

Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

by CTG

in Lymphoma

Other

California

Deadline:

02/27/2026

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

by CTG

in Lymphoma, Lymphoma, Large B-Cell, Diffuse

Other

Florida

Deadline:

09/15/2029

Long-Term Follow-up Study

by CTG

in Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma

Other

Alabama

Deadline:

12/01/2041

Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma

by CTG

in Lymphoma

Other

Minnesota

Deadline:

04/01/2027

UPLYFT For Lymphoma Survivors

by CTG

in Lymphoma, Survivorship

Other

Massachusetts

Deadline:

03/31/2026

Odronextamab in Low Tumor Volume Advanced FL

by CTG

in Lymphoma, Follicular Lymphoma

Other

Massachusetts

Deadline:

01/02/2028

A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia

by CTG

in Lymphoma, Leukemia

Other

California

Deadline:

03/03/2035

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

by CTG

in Lymphoma, Solid Tumor, CNS Tumors, Somatostatin Receptor Positive, NETs

Other

Pennsylvania

Deadline:

04/01/2034

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

by CTG

in Lymphoma

Other

Texas

Deadline:

01/31/2034

Load more All clinical trials loaded.

Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

Long-Term Follow-up Study

Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma

UPLYFT For Lymphoma Survivors

Odronextamab in Low Tumor Volume Advanced FL

A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps

Get new clinical trials sent to you?

Paid Clinical Trials for Lymphoma

Filter Results:

Follow us on social media:

Participants

Organizations

Products

About Us

Mobile Apps